What is the branded version of bevacizumab?

The branded version of bevacizumab is Avastin. Avastin is the trade name under which bevacizumab is marketed for various cancer treatments, such as metastatic colorectal cancer, non-squamous non-small cell lung cancer, and other conditions. Understanding the nuances between different forms of bevacizumab can be crucial, especially in contexts such as ophthalmology, where it is sometimes used off-label to treat conditions like age-related macular degeneration (AMD) and other causes of choroidal neovascularization (CNV).

While other options mention various formulations or alternative branding of bevacizumab, only Avastin is the recognized and widely used branded version. Lucentis, on the other hand, is a different monoclonal antibody (ranibizumab) specifically designed for ocular conditions, and the other two choices represent names for biosimilar products that may vary by manufacturer but are not the original branded version.